Lonza has announced the launch of two new TheraPEAK® products—AmpliCell® Cytokines and TheraPEAK® 293-GT® Medium—to reinforce its offerings in the cell and gene therapy landscape. These GMP-compliant tools are designed to help labs achieve more consistent, biologically relevant results from research through to manufacturing.
AmpliCell® Cytokines
AmpliCell® Cytokines are engineered to:
- Optimize immune cell expansion and differentiation
- Maintain high batch-to-batch consistency
- Facilitate a seamless transition from discovery to GMP production
Developed in a mammalian expression system, these cytokines provide native-like folding and glycosylation, essential for high-performance applications in sensitive cell therapy workflows.
293-GT® Medium: Supporting Efficient AAV Production
The new TheraPEAK® 293-GT® Medium is a chemically defined, animal-origin-free formulation that supports adeno-associated virus (AAV) production in suspension HEK293 cells. Offered as a two-part system—growth medium plus supplement—it is designed for easy integration into current lab workflows.
Benefits include:
- High AAV yields and favorable full-to-empty capsid ratios
- Compatibility with common transfection reagents and enhancers
- Robust scalability and regulatory readiness
With more than 130 clinical trials and FDA-approved therapies supported by the TheraPEAK® range, these new additions offer lab managers dependable solutions to streamline operations and accelerate development timelines.
"The introduction of AmpliCell® Cytokines and the 293-GT® Medium to our TheraPEAK® Range greatly enhances our offering for cell and gene therapy customers, providing them with reliable solutions to support their drug development efforts," said Mike Goetter, Head of Bioscience, Specialized Modalities, Lonza.
